Skip to main content

Advertisement

SpringerLink
Log in

Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Hochhaus A, Larson RA, Guilhot F, IRIS Investigators et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917–927. https://doi.org/10.1056/NEJMoa1609324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Swerdlow SH, Campo E, Harris NL et al (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised, 4th edn. Lyon, International Agency for Research on Cancer (IARC)

    Google Scholar 

  3. Bloch J, Spertini O, Stucki A et al (2018) Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia. Leuk Res 73:103–104. https://doi.org/10.1016/j.leukres.2018.09.002

    Article  PubMed  Google Scholar 

  4. Mahon FX, Réa D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035

    Article  CAS  PubMed  Google Scholar 

  5. Ross DM, Branford S, Seymour JF et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515–522

    Article  CAS  PubMed  Google Scholar 

  6. Vetrie D, Helgason GV, Copland M (2020) The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer 20:158–173. https://doi.org/10.1038/s41568-019-0230-9

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service and Central Laboratory of Haematology, Lausanne University Hospital (CHUV), Lausanne, Switzerland

    Julien Dereme, Sophie Voruz, Françoise Solly & Sabine Blum

  2. Lausanne University (UNIL), Lausanne, Switzerland

    Jacqueline Schoumans & Sabine Blum

  3. Oncogenomic Laboratory, Lausanne University Hospital (CHUV), Lausanne, Switzerland

    Jacqueline Schoumans

Authors
  1. Julien Dereme
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Voruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Françoise Solly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacqueline Schoumans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sabine Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SV, JD and SB were in charge of the patient, did the literature review and wrote the manuscript. FS and JS performed the genetic and molecular analyses and wrote part of the manuscript.

Corresponding author

Correspondence to Sophie Voruz.

Ethics declarations

Ethics approval

Informed consent was obtained from the patient.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dereme, J., Voruz, S., Solly, F. et al. Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript. Ann Hematol 103, 1027–1029 (2024). https://doi.org/10.1007/s00277-023-05600-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05600-z

Search

Navigation